Xiaoping Jin

3.5k total citations · 3 hit papers
70 papers, 2.7k citations indexed

About

Xiaoping Jin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Xiaoping Jin has authored 70 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 17 papers in Surgery. Recurrent topics in Xiaoping Jin's work include Cancer Immunotherapy and Biomarkers (34 papers), Bladder and Urothelial Cancer Treatments (14 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). Xiaoping Jin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (34 papers), Bladder and Urothelial Cancer Treatments (14 papers) and Monoclonal and Polyclonal Antibodies Research (12 papers). Xiaoping Jin collaborates with scholars based in United States, China and United Kingdom. Xiaoping Jin's co-authors include Ashok Gupta, Bradley P. Carlin, Sudipto Banerjee, Peter H. O’Donnell, Christophe Massard, Yong Ben, Marlon C. Rebelatto, Joyce Antal, John A. Blake-Haskins and Neil H. Segal and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Xiaoping Jin

67 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

2017 664 citations Peter H. O’Donnell, Christophe Massard et al. profile →
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

2016 661 citations Christophe Massard, Michael S. Gordon et al. Journal of Clinical Oncology profile →
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

2025 16 citations Yongmei Yin, Ying Fan et al. Nature Medicine profile →

Peers

Countries citing papers authored by Xiaoping Jin

Since Specialization

Citations

This map shows the geographic impact of Xiaoping Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoping Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoping Jin more than expected).

Fields of papers citing papers by Xiaoping Jin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoping Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoping Jin. The network helps show where Xiaoping Jin may publish in the future.

Co-authorship network of co-authors of Xiaoping Jin

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoping Jin. A scholar is included among the top collaborators of Xiaoping Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoping Jin. Xiaoping Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial breakdown → 2025 ·Nature Medicine ·Yongmei Yin, Ying Fan, (unknown), (unknown), Xiaojia Wang, Wěi Li, Man Li, Xi Yan, Shusen Wang, Tao Sun, (unknown), (unknown), Zhongsheng Tong, (unknown), (unknown), Xiaoping Jin, (unknown), (unknown), Binghe Xu	16
2	Modified versus traditional subcostal anterior quadratus lumborum block for postoperative analgesia after laparoscopic nephrectomy: a randomized-controlled study 2025 ·Journal of Anesthesia ·Huili Li, Danxu Ma, (unknown), (unknown), Yun Wang, Xiaoping Jin	0
3	Abstract CT247: Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study 2024 ·Cancer Research ·Wenfeng Fang, Ying Cheng, Zhendong Chen, (unknown), Yongsheng Li, Yongmei Yin, Xingya Li, Huiting Xu, Guohua Yu, Yanjun Mi, Zev A. Wainberg, Jordi Rodón, Xiang Wang, Xian Wang, (unknown), Xiaoping Jin, Lian Lu, (unknown), Jin Li, Li Zhang	12
4	Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers 2022 ·Cancer Immunology Immunotherapy ·Yulong Zheng, Anna Rachelle Mislang, Jermaine Coward, Rasha Cosman, Adam Cooper, Craig Underhill, Jianqing Zhu, Jianping Xiong, Ou Jiang, Hong Wang, (unknown), (unknown), Xiaoping Jin, Baiyong Li, Zhongmin Maxwell Wang, (unknown), (unknown), Yu Xia, Nong Xu	14
5	436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy 2021 ·Regular and Young Investigator Award Abstracts ·Hai‐Qiang Mai, Shaojun Lin, Dongping Chen, Xiaozhong Chen, Song Qu, Qin Lin, Ying Luo, Chunhong Hu, Dehua Wu, (unknown), Feng Jin, Nianyong Chen, (unknown), (unknown), Xiaoping Jin, (unknown), Yu Xia, Rui‐Hua Xu	14
6	Optimal PD-L1–high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy 2020 ·PLoS ONE ·M Zając, Jiabu Ye, Pralay Mukhopadhyay, Xiaoping Jin, Yong Ben, Joyce Antal, Ashok Gupta, Marlon C. Rebelatto, J. Andrew Williams, Jill Walker	16
7	C. aromaticus leaf extract mediated synthesis of Zinc oxide nanoparticles and their antimicrobial activity towards clinically multidrug-resistant bacteria isolated from pneumonia patients in nursing care 2020 ·Materials Research Express ·Yan Hou, (unknown), Yan Ren, Yan Shi, Xiaoping Jin, (unknown), (unknown)	11
8	A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors 2019 ·Journal for ImmunoTherapy of Cancer ·Ben Markman, Ben Tran, Hui Gan, Amy Prawira, Jermaine Coward, Xiaoping Jin, Baiyong Li, (unknown), Yu Xia, Jayesh Desai, Michael Millward	3
9	Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients 2019 ·Clinical Lung Cancer ·Sriram Sridhar, Luis Paz‐Ares, Hao Liu, Kui Shen, Chris Morehouse, Naiyer A. Rizvi, Neil H. Segal, Xiaoping Jin, (unknown), Rajesh Narwal, Ashok Gupta, Phillip A. Dennis, Jiabu Ye, Pralay Mukhopadhyay, Brandon W. Higgs, Koustubh Ranade	37
10	A phase I/II study of the anti-programmed cell death-1 (PD-1) antibody AK105 in patients with relapsed or refractory classic Hodgkin lymphoma (cHL). 2019 ·Journal of Clinical Oncology ·Yuqin Song, Jun Zhu, Ningjing Lin, Chen Zhang, Xiaoping Jin, (unknown), Baiyong Li, Yu Xia	1
11	Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma 2018 ·Archives of Pathology & Laboratory Medicine ·Magdalena Zając, Anne-Marie Boothman, Yong Ben, Ashok Gupta, Xiaoping Jin, Amita Mistry, Constantine Sabalos, (unknown), (unknown), Craig Barker, Joyce Antal, Peiyi Wang, Pallavi Patil, (unknown), Marlon C. Rebelatto, Jill Walker	18
12	Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non–Small Cell Lung Cancer Tissue 2017 ·Biomarker Insights ·(unknown), (unknown), Xiaoping Jin, Kenji Nakamaru, Matthias Schneider, Robert A. Beckman, Daniel J. Freeman, (unknown), Wenqin Feng	4
13	Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma 2016 ·Diagnostic Pathology ·Marlon C. Rebelatto, Anita Midha, Amita Mistry, Constantine Sabalos, (unknown), Xia Li, Xiaoping Jin, Keith E. Steele, Paul B. Robbins, John A. Blake-Haskins, Jill Walker	135
14	Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer breakdown → 2016 ·Journal of Clinical Oncology ·Christophe Massard, Michael S. Gordon, Sunil Sharma, Saeed Rafii, Zev A. Wainberg, Jason J. Luke, Tyler J. Curiel, Gerardo Colón‐Otero, Omid Hamid, Rachel E. Sanborn, Peter H. O’Donnell, Alexandra Drakaki, Winston Tan, John F. Kurland, Marlon C. Rebelatto, Xiaoping Jin, John A. Blake-Haskins, Ashok Gupta, Neil H. Segal	661
15	[Changes of thyroid function, thyroid antibodies and urinary iodine among permanent residents of Urumqi in Xinjiang]. 2015 ·PubMed ·Xinling Wang, (unknown), (unknown), Yanying Guo, (unknown), Hongli Zhao, (unknown), Xiaoping Jin, Huili Wang, (unknown)	1
16	Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer 2013 ·Cancer Medicine ·Andres Forero‐Torres, Jeffrey R. Infante, David Waterhouse, Lucas Wong, Selwyn M. Vickers, Edward Arrowsmith, Aiwu Ruth He, Lowell L. Hart, David Trent, James L. Wade, Xiaoping Jin, Qiang Wang, (unknown), Michael Rosen, Robert A. Beckman, Reinhard von Roemeling, Jonathan Greenberg, Mansoor N. Saleh	72
17	Non-parametric interval estimation for the partial area under the ROC curve 2011 ·Canadian Journal of Statistics ·Gengsheng Qin, Xiaoping Jin, Xiao‐Hua Zhou	6
18	Initial Combination Therapy with Metformin and Colesevelam for Achievement of Glycemic and Lipid Goals Min Early Type 2 Diabetes 2010 ·Endocrine Practice ·Julio Rosenstock, Vivian Fonseca, W. Timothy Garvey, Ronald Goldberg, Yehuda Handelsman, Stacey L. Abby, (unknown), Xiaoping Jin, Soamnauth Misir, Sukumar Nagendran, Michael R. Jones	31
19	Multivariate Parametric Spatiotemporal Models for County Level Breast Cancer Survival Data 2005 ·Lifetime Data Analysis ·Xiaoping Jin, Bradley P. Carlin	15
20	Generalized Hierarchical Multivariate CAR Models for Areal Data 2005 ·Biometrics ·Xiaoping Jin, Bradley P. Carlin, Sudipto Banerjee	147

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact